publication . Other literature type . Article . 2019

Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology.

Ibrahima Diouf; Ashley Bush; Scott Ayton;
Open Access
  • Published: 18 Feb 2019
  • Publisher: Springer Science and Business Media LLC
: Cortical iron has been shown to be elevated in Alzheimer's disease (AD), but the impact of the directly measured iron on the clinical syndrome has not been assessed. We investigated the association between post-mortem iron levels with the clinical and pathological diagnosis of AD, its severity, and the rate of cognitive decline in the 12 years prior to death in subjects from the Memory and Aging Project (n = 209). Iron was elevated (β [SE] = 9.7 [2.6]; P = 3.0 × 10-4) in the inferior temporal cortex only in subjects who were diagnosed with clinical AD during life and had a diagnosis of AD confirmed post-mortem by standardized criteria. Although iron was weakly...
free text keywords: Article, Molecular Biology, Cellular and Molecular Neuroscience, Psychiatry and Mental health
Funded by
NIH| Neuropathologic-Epidemiological Study of Metallomics and Alzheimer's Disease
  • Funder: National Institutes of Health (NIH)
  • Project Code: 1RF1AG054057-01
NIH| Epidemiologic Study of Neural Reserve and Neurobiology of Aging
  • Funder: National Institutes of Health (NIH)
  • Project Code: 3R01AG017917-11A1S1
46 references, page 1 of 4

1.Price JL, Morris JC. Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Annals of neurology 1999; 45(3): 358–368.10072051 [PubMed]

2.Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND Frequent amyloid deposition without significant cognitive impairment among the elderly. Archives of neurology 2008; 65(11): 1509–1517.19001171 [OpenAIRE] [PubMed]

3.Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006; 66(12): 1837–1844.16801647 [PubMed]

4.Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006; 67(3): 446–452.16894106 [OpenAIRE] [PubMed]

5.Rowe CC, Bourgeat P, Ellis KA, Brown B, Lim YY, Mulligan R Predicting Alzheimer disease with beta-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. Annals of neurology 2013; 74(6): 905–913.24448836 [OpenAIRE] [PubMed]

6.Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC Cerebrospinal Fluid Biomarker Signature in Alzheimer’s Disease Neuroimaging Initiative Subjects. Annals of neurology 2009; 65(4): 403–413.19296504 [OpenAIRE] [PubMed]

7.Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 2007; 69(7): 631–639.17698783 [PubMed]

8.Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Archives of neurology 2007; 64(3): 343–349.17210801 [PubMed]

9.Lim YY, Maruff P, Pietrzak RH, Ames D, Ellis KA, Harrington K Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer’s disease. Brain : a journal of neurology 2014; 137(Pt 1): 221–231.24176981 [PubMed]

10.Tao Y, Wang Y, Rogers JT, Wang F. Perturbed iron distribution in Alzheimer’s disease serum, cerebrospinal fluid, and selected brain regions: a systematic review and meta-analysis. Journal of Alzheimer’s disease : JAD 2014; 42(2): 679–690.24916541 [PubMed]

11.Schneider SA, Hardy J, Bhatia KP. Syndromes of neurodegeneration with brain iron accumulation (NBIA): an update on clinical presentations, histological and genetic underpinnings, and treatment considerations. Movement disorders : official journal of the Movement Disorder Society 2012; 27(1): 42–53.22031173 [PubMed]

12.Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell 2017; 171(2): 273–285.28985560 [OpenAIRE] [PubMed]

13.Ayton S, Faux NG, Bush AI, Alzheimer’s Disease Neuroimaging Initiative I. Ferritin levels in the cerebrospinal fluid predict Alzheimer’s disease outcomes and are regulated by APOE. Nature communications 2015; 6: 6760.

14.Ayton S, Faux NG, Bush AI. Association of Cerebrospinal Fluid Ferritin Level With Preclinical Cognitive Decline in APOE-epsilon4 Carriers. JAMA neurology 2017; 74(1): 122–125.27893873 [PubMed]

15.Ayton S, Fazlollahi A, Bourgeat P, Raniga P, Ng A, Lim YY Cerebral quantitative susceptibility mapping predicts amyloid-beta-related cognitive decline. Brain : a journal of neurology 2017; 140(8): 2112–2119.28899019 [OpenAIRE] [PubMed]

46 references, page 1 of 4
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue